Recent Comments
- LB on The final House report on COVID
- Joy Smith on The Declaration of Pandemics
- Linnea Comstock on The Declaration of Pandemics
- Lance W Richardson on The Declaration of Pandemics
- Sarah on The Declaration of Pandemics
Most Viewed Posts
- Exclusive: Why the COVID “mRNA” vaccines are actually DNA gene therapies that must be removed from the market (23,388)
- Pfizer admits in federal court that the COVID gene therapies were never approved through the FDA (17,578)
- New treatment paradigm for C. Diff colitis (16,034)
- The Healthcare Channel hits 10 (15,421)
- Gordon Guyatt, MD: Update on the problem of clinical trials being stopped early to inflate efficacy of drugs (15,278)
- How the FDA regulates compounding pharmacies (15,107)
- I discuss the handling of the COVID-19 outbreak on The Joe Piscopo radio show (14,952)
- The Who’s Teen Cancer Lounge at Sloan Kettering opens (10,871)
- The new CDC guidelines for prescribing opioid pain pills (10,369)
- Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital. (10,234)
Pages
Categories
- – Biotech
- – Generics
- – JAMA
- – Medical Devices
- – NEJM
- – Opinion
- – Pharma
- – Policy
- – Reviews, books, devices
- – The Weekly Summary
- Bariatric surgery
- Cardiac surgery
- Cardiology
- Dermatology
- Diabetes and endocrinology
- Emergency medicine
- Gastroenterology and liver
- General surgery
- Genetics
- Geriatrics
- Infectious disease
- Internal Medicine
- Neurology
- Neurosurgery
- Nutrition
- Obstetrics and Gynecology
- Oncology
- Ophthalmology
- Orthopedic surgery
- Pediatrics
- Plastic surgery
- Primary care medicine
- Psychology Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Spine surgery
- Sports medicine
- Transplant surgery
- Trauma Surgery
- Uncategorized
- Urology
- Vascular Surgery
- Z Medical centers
- Baylor
- Boston University
- Cedars Sinai
- Cleveland Clinic
- Columbia
- Cornell
- Duke
- Emory
- George Washington Univ
- Harvard
- Henry Ford
- Iowa State
- Johns Hopkins
- Mayo Clinic
- McMaster University
- Medical University of South Carolina
- Memorial Sloan-Kettering
- Michigan
- National Jewish Health
- NYU
- Ohio State
- Oregon Health and Science University
- UC Davis
- UC San Francisco
- UCLA
- Univ Kentucky
- Univ Maryland
- Univ Miami
- Univ Michigan
- Univ of Louisville
- Univ Texas
- VA Walter Reed
- Vanderbilt
- VCU
- Washington University
- Yale
Category Archives: UCLA
The Daltrey Townshend teenage and young adult cancer center at UCLA
May 4, 2014- Interviewed by Steven E. Greer More than 20 years ago, Roger Daltrey began forming special cancer units in the UK to treat patients in their teenage
Posted in - Opinion, Oncology, Rehab, UCLA
Leave a comment
Interview with Simon Townshend about the Daltrey/Townshend Teen Cancer Program
The Daltrey Townshend teenage and young adult cancer center at UCLA
Posted in Oncology, UCLA
Leave a comment
Robotic surgery and controversies
January 24, 2014- Dr. Dutson gives an update on the referral patterns and safety concerns over the Da Vinci system.
Posted in General surgery, UCLA
Leave a comment
The best hospitals in the country are losing money. Why?
August 12, 2019- by Steven E. Greer, MD In the course of working on a medical book for the patient population, I just discovered this 2017 Forbes article that explains
Posted in - Policy, Cleveland Clinic, CMS, Columbia, Congress, Cornell, Harvard, NYU, Ohio State, UCLA, Univ Miami, Z Medical centers
Comments Off on The best hospitals in the country are losing money. Why?
BRAF and MEK combos for melanoma
Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year.
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Review of immunotherapy and targeted therapy
June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways
March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Review of combination immunotherapies seen at ASCO 2016
June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?
September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Ibrance (palbociclib) to treat advanced breast cancer
November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,
Review of the TAVR data from the 2015 ACC
May 7, 2015- Interviewed by Steven E. Greer, MD
Posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA
Leave a comment
The newly approved Edwards Lifesciences Sapien 3 aortic valve
July 5, 2015- Interviewed by Steven E. Greer, MD We interviewed William Suh, MD of UCLA about the newly approved Edwards Lifesciences Sapien
Posted in - Medical Devices, Cardiac surgery, Cardiology, FDA, UCLA
Leave a comment
Drug-coated balloons to treat fem-pop disease
April 27, 2014– Interviewed by Steven E. Greer, MD At the Charing Cross symposium in London, Medtronic reported results of the IN-PACT trial
Posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA
Leave a comment
The subcutaneous ICD
The concept of applying high voltage to shock a heart out of
Posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA
Leave a comment
New therapies for hepatitis C
November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care
Serelaxin to treat acute heart failure
July 8, 2013- The FDA granted Novartis the coveted “Breakthrough” status for drug serelaxin
Posted in Cardiology, UCLA
Leave a comment
anti-PD1 and anti-PD-L1 drugs treating NSCLC
March 26, 2013 Interviewed By Steven E. Greer, MD
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
New therapies for Multiple Sclerosis
Interviewed by Steven E. Greer, MD Barbara Giesser, MD, neurologist and Medical Director of the Multiple Sclerosis Center at UCLA, discusses the
Posted in Neurology, UCLA, Uncategorized
Leave a comment